← Phathom Pharmaceuticals, Inc. (PHAT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Phathom Pharmaceuticals, Inc. (PHAT)
Pharmaceutical Preparations · market cap $595M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-29 (est.)
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Phathom Pharmaceuticals (PHAT) is a commercial-stage specialty pharma company focused on gastrointestinal diseases, with three Phase 3 assets: amoxicillin and lansoprazole for H. pylori and erosive esophagitis, respectively, and vonoprazan for non-erosive GERD. The company generated $175M in revenue in 2025, up sharply from $55M in 2024, but remains deeply unprofitable with a $221M net loss. With $180.9M in cash and ~35 months of runway, the near-term focus is on commercialization execution and a vonoprazan Phase 2 readout expected around December 2026.
The catalyst path
- 2026-10-29 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 2 · Vonoprazanimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Lansoprazole | Phase 3 | Erosive Esophagitis |
| Vonoprazan | Phase 3 | Non-Erosive Gastro-Esophageal Reflux Disease |
Price & technical context
3-month
-36.8%
6-month
-36.4%
12-month
-39.8%
52-wk range
$6.99–$18.08
vs 50-day MA
-19.6%
vs 200-day MA
-38.1%
Realized vol
66.3%
Max drawdown
-88.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PHAT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.